Overview

Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma

Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
A prospective, open label, single-center, early feasibility trial will be conducted to assess the safety and feasibility of a home-based Static Magnetic and Electric (sBE) device applied for 8 hours/day during sleep in adult participants with recurrent glioblastoma (rGBM) at their first relapse.
Phase:
N/A
Details
Lead Sponsor:
Varun Monga, MD
Collaborator:
University of Iowa
Treatments:
Bevacizumab
Lomustine